Jon Congleton
Director; Director, Chief Executive Officer · 9 filings · Latest: Sep 30, 2026
Avalyn Pharma Inc.
IMMUNIC, INC.
Mineralys Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
MLYS | Jon Congleton | Director, Chief Executive Officer | Sep 30, 2026 | Sale | $25.46 | 75,000 | $1.9M | 528,621 | |
MLYS | Congleton Jon | — | Sep 30, 2026 | Proposed Sale | $25.46 | 75,000 | $1.9M | — | |
MLYS | Jon Congleton | Director, Chief Executive Officer | Jul 13, 2026 | Sale | $27.24 | 10,700 | $291.4K | 603,621 | |
MLYS | Congleton Jon | — | Jul 13, 2026 | Proposed Sale | $27.24 | 10,700 | $291.4K | — | |
MLYS | Jon Congleton | Director, Chief Executive Officer | Jun 30, 2026 | Sale | $26.14 | 75,000 | $2.0M | 614,321 | |
MLYS | Congleton Jon | — | Jun 30, 2026 | Proposed Sale | $26.14 | 75,000 | $2.0M | — | |
MLYS | Jon Congleton | Director, Chief Executive Officer | Apr 13, 2026 | Sale | $26.83 | 15,730 | $422.0K | 689,321 | |
MLYS | Congleton Jon | — | Apr 13, 2026 | Proposed Sale | $26.83 | 15,730 | $422.0K | — | |
MLYS | Jon Congleton | Director, Chief Executive Officer | Mar 31, 2026 | Sale | $26.27 | 75,000 | $2.0M | 705,051 | |
MLYS | Congleton Jon | — | Mar 31, 2026 | Proposed Sale | $26.27 | 75,000 | $2.0M | — | |
MLYS | Congleton Jon | — | Jan 12, 2026 | Proposed Sale | $32.62 | 16,236 | $529.6K | — | |
MLYS | Congleton Jon | — | Nov 11, 2025 | Proposed Sale | $45.44 | 200,000 | $9.1M | — | |
MLYS | Congleton Jon | — | Oct 13, 2025 | Proposed Sale | $42.67 | 15,100 | $644.3K | — | |
MLYS | Congleton Jon | — | Jul 11, 2025 | Proposed Sale | $14.51 | 15,884 | $230.4K | — | |
MLYS | Congleton Jon | — | Apr 11, 2025 | Proposed Sale | $12.19 | 15,319 | $186.8K | — | |
MLYS | Congleton Jon | — | Jan 13, 2025 | Proposed Sale | $9.06 | 18,333 | $166.1K | — | |
MLYS | Congleton Jon | — | Oct 11, 2024 | Proposed Sale | $13.52 | 15,271 | $206.4K | — |